Elite Diagnostic Limited(ELITE)

Unaudited financials for the six months ended December 31, 2025:

Elite Diagnostic Limited (ELITE) for the six months ended December 31, 2025 reported a 2% increase in revenue totaling $408.85 million compared to $401.73 million in the corresponding period last year. Revenue for the second quarter had a 4% decrease to close at $191.55 million compared to $198.86 million for the comparable quarter of 2024.

Year to date, Direct Cost amounted to $93.48 million (2024: 109.36 million), this represents a decrease of 15% year over year. Consequently, gross profit increased by 8% to $315.37 million compared to $292.36 million for the six months ended December 31, 2024. The company booked gross profit of $149.40 million for the second quarter versus $149.50 million reported for the similar quarter of 2024.

Administrative expenses decreased by 1% to close at $205.34 million (2024: $207.81 million), while depreciation increased by 5% from $84.33 million in 2024 to $88.75 million in the period under review. As a result, operating profit for the six months ended December 31, 2025 amounted to $21.28 million, a 9485% increase relative to $222,000 reported in 2024.

Foreign Gain for the six months ended December 31, 2025, amounted to $1.18 million, a 7% increase relative to $1.10 million reported in 2024. Additionally, Other income increased by 2513% to $810,000 (2024: $31,000)

Year to date, Finance costs totaled $22.10 million, a 16% increase from the corresponding period last year. (2024: $19.01 million).

Profit before tax for the six months ended December 31, 2025, amounted to $1.17 million (2024: Loss of $17.65 million). Loss before tax for the second quarter amounted to $11.27 million (2024: Loss of $6.21 million).

Income Tax for the six months ended December 31, 2025, amounted to $552,000 (2024: nil) . Net Profit for the six months amounted to $617,000, a 103% increase from the net loss of $17.65 million reported in 2024. For the second quarter, Net loss was $11.48 million (2024: Loss of $6.21 million).

Consequently, Earnings Per Share for the six months amounted to $0.002 (2024: LPS: $0.05), while Loss Per Share for the quarter totaled $0.03 (2024: LPS: $0.02). The twelve-month trailing EPS was $0.14, and the number of shares used in these calculations was 353,400,000.

Notably, ELITE’s stock price closed the trading period on February 13, 2026, at a price of $1.53 with a corresponding P/E ratio of 10.26x.

Balance Sheet Highlights

The company’s assets totaled $1.06 billion (2024: $999.93 million). The movement in total assets was mainly attributable to 1022% increase in ‘Cash and cash equivalents’ amounting to $184.37 million (2024: $16.44 million)

Shareholder’s equity was $543.62 million (2024: $493.33 million), representing a book value per share of $1.54 (2024: $1.40).

Analyst Certification -The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view (s) expressed by that research analyst in this research report.

Company Disclosure -The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.